$CUEN
Cuentas Inc. Stock $cuen

$cuen Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024032958 Filed on April 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023 Q2
Revenue	$639.0K	$1.346M	$40.00K
YoY Change	898.44%	71.03%	-94.03%
Cost Of Revenue	$708.0K	$1.486M	$153.0K
YoY Change	475.61%	145.21%	-75.12%
Gross Profit	-$69.00K	-$140.0K	-$113.0K
YoY Change	16.95%	-177.35%	-305.45%
Gross Profit Margin	-10.8%	-10.4%	-282.5%
Selling, General & Admin	$772.0K	$2.512M	$776.0K
YoY Change	-52.49%	71.0%	-71.72%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$4.000K	$1.000K	$5.000K
YoY Change	100.0%	-99.78%	-98.89%
% of Gross Profit
Operating Expenses	$774.0K	$2.510M	$780.0K
YoY Change	-52.43%	30.66%	-75.59%
Operating Profit	-$843.0K	-$2.650M	-$893.0K
YoY Change	-50.0%	52.3%	-71.57%
Interest Expense	$5.000K	$4.715M	-$7.000K
YoY Change	-600.0%	47050.0%	-333.33%
% of Operating Profit
Other Income/Expense, Net	$398.0K	$96.00K	-$517.0K
YoY Change	512.31%	-196.0%	1420.59%
Pretax Income	-$445.0K	$2.161M	-$1.403M
YoY Change	-73.61%	-139.8%	-55.81%
Income Tax
% Of Pretax Income
Net Earnings	-$445.0K	$2.098M	-$1.412M
YoY Change	-73.75%	-138.52%	-55.68%
Net Earnings / Revenue	-69.64%	155.87%	-3530.0%
Basic Earnings Per Share	-$0.15		-$0.67
Diluted Earnings Per Share	-$0.15	$0.67	-$0.67
COMMON SHARES
Basic Shares Outstanding	2.730M shares	2.720M shares	2.103M shares
Diluted Shares Outstanding	2.720M shares		2.103M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.00K	$205.0K	$271.0K
YoY Change	-99.16%	-56.01%	-84.93%
Cash & Equivalents	$28.00K	$205.0K	$271.0K
Short-Term Investments
Other Short-Term Assets	$5.000K	$76.00K	$36.00K
YoY Change	-90.38%	442.86%	-63.64%
Inventory
Prepaid Expenses
Receivables	$290.0K	$7.000K	$233.0K
Other Receivables	$459.0K	$1.472M	$311.0K
Total Short-Term Assets	$492.0K	$1.760M	$628.0K
YoY Change	-86.66%	155.44%	-69.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.00K	$13.00K	$5.000K
YoY Change	83.33%	116.67%	-44.44%
Goodwill
YoY Change
Intangibles	$17.00K	$19.00K	$100.0K
YoY Change	-34.62%	-32.14%	-97.79%
Long-Term Investments	$2.928M	$2.928M	$3.000M
YoY Change	99.46%	277.32%	232.59%
Other Assets
YoY Change
Total Long-Term Assets	$2.956M	$2.960M	$3.105M
YoY Change	97.07%	265.43%	-42.96%
TOTAL ASSETS
Total Short-Term Assets	$492.0K	$1.760M	$628.0K
Total Long-Term Assets	$2.956M	$2.960M	$3.105M
Total Assets	$3.448M	$4.720M	$3.733M
YoY Change	-33.55%	214.88%	-50.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.107M	$1.497M	$1.286M
YoY Change	72.14%	21.61%	-32.99%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$163.0K	$26.00K	$115.0K
YoY Change	45.54%	-76.15%	11.65%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.741M	$4.689M	$2.173M
YoY Change	68.44%	119.73%	-38.56%
LONG-TERM LIABILITIES
Long-Term Debt	$102.0K	$101.0K	$89.00K
YoY Change	14.61%	13.48%	0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$102.0K	$101.0K	$89.00K
YoY Change	14.61%	13.48%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.741M	$4.689M	$2.173M
Total Long-Term Liabilities	$102.0K	$101.0K	$89.00K
Total Liabilities	$3.843M	$4.790M	$2.262M
YoY Change	66.36%	115.47%	-37.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$55.39M	-$54.95M	-$55.86M
YoY Change	1.74%	4.16%	24.05%
Common Stock	$55.03M	$54.91M	$2.000K
YoY Change	2751350.0%	288894.74%	-86.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$33.00K
YoY Change
Treasury Stock Shares
Shareholders Equity	-$395.0K	$2.500M	$1.471M
YoY Change
Total Liabilities & Shareholders Equity	$3.448M	$4.720M	$3.733M
YoY Change	-33.55%	214.88%	-50.03%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023 Q2
OPERATING ACTIVITIES
Net Income	-$445.0K	$2.098M	-$1.412M
YoY Change	-73.75%	-138.52%	-55.68%
Depreciation, Depletion And Amortization	$4.000K	$1.000K	$5.000K
YoY Change	100.0%	-99.78%	-98.89%
Cash From Operating Activities	-$310.0K	-$992.0K	-$900.0K
YoY Change	-78.66%	-38.54%	-53.12%
INVESTING ACTIVITIES
Capital Expenditures		$161.0K	$78.00K
YoY Change
Acquisitions			$850.0K
YoY Change
Other Investing Activities	$0.00	$301.0K	-$2.079M
YoY Change			236.95%
Cash From Investing Activities		$140.0K	-$2.157M
YoY Change			249.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$133.0K	0.000	0.000
YoY Change	-96.92%	-100.0%
NET CHANGE
Cash From Operating Activities	-$310.0K	-992.0K	-900.0K
Cash From Investing Activities		140.0K	-2.157M
Cash From Financing Activities	$133.0K	0.000	0.000
Net Change In Cash	-$177.0K	-852.0K	-3.057M
YoY Change	-106.18%	-48.11%	20.5%
FREE CASH FLOW
Cash From Operating Activities	-$310.0K	-$992.0K	-$900.0K
Capital Expenditures		$161.0K	$78.00K
Free Cash Flow		-$1.153M	-$978.0K
YoY Change		-28.56%	-49.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1532000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2317213	shares
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-54923
CY2023	dei	Entity Registrant Name EntityRegistrantName	CUENTAS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3537265
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	235 Lincoln Rd
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami Beach
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33139
CY2023	dei	City Area Code CityAreaCode	800
CY2023	dei	Local Phone Number LocalPhoneNumber	611-3622
CY2023	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par valueWarrants
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	5240809	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2730058	shares
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	1024
CY2023	dei	Auditor Name AuditorName	Yarel + Partners
CY2023	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	205000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	466000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	76000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	14000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1760000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	689000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	2928000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	776000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	19000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	28000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2960000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	810000	usd
CY2023Q4	us-gaap	Assets Assets	4720000	usd
CY2022Q4	us-gaap	Assets Assets	1499000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1497000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1231000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2230000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	681000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	785000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	151000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	113000	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26000	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	109000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4689000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2134000	usd
CY2023Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	101000	usd
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	89000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	101000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	89000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4790000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2223000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	11076923	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2719668	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2719668	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1473645	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1473645	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	54906000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	52053000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	33000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	29000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54946000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52750000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-70000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-724000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4720000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1499000	usd
CY2023	us-gaap	Revenues Revenues	2346000	usd
CY2022	us-gaap	Revenues Revenues	2994000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	2733000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	2508000	usd
CY2023	us-gaap	Gross Profit GrossProfit	-387000	usd
CY2022	us-gaap	Gross Profit GrossProfit	486000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1810000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3600000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6011000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9431000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	6022000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	14841000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-6409000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-14355000	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	441000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	132000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	usd
CY2023	cuen	Gain On Fair Value Measurement Of Stock Based Liabilities GainOnFairValueMeasurementOfStockBasedLiabilities	4741000	usd
CY2022	cuen	Gain On Fair Value Measurement Of Stock Based Liabilities GainOnFairValueMeasurementOfStockBasedLiabilities	2000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4300000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-124000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2109000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14479000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-87000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-52000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2196000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14531000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.81
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2317213	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1230577	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9450000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2689000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1587000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	110000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	29000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14531000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-724000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	622000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	700000	usd
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	4000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2196000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-70000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2196000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14531000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	622000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1697000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-87000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-52000	usd
CY2023	us-gaap	Interest Expense InterestExpense	-70000	usd
CY2022	us-gaap	Interest Expense InterestExpense	12000	usd
CY2022	cuen	Loan To Cuentas Sdillc That Was Not Repaid LoanToCuentasSDILLCThatWasNotRepaid	100000	usd
CY2022	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	157000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6852000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3000	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3127000	usd
CY2023	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	545000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3600000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1810000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1102000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	588000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-4000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	87000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-148000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	172000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	299000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	421000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1548000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-445000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	39000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-570000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4193000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8137000	usd
CY2023	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	2085000	usd
CY2022	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	657000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	303000	usd
CY2023	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	301000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2098000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-664000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6034000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2689000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	29000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6030000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2660000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-261000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6141000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6607000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	205000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466000	usd
CY2022	cuen	Investment In Nonconsolidated Entity In Nonconsolidated Entity Against Accounts Receivables InvestmentInNonconsolidatedEntityInNonconsolidatedEntityAgainstAccountsReceivables	233000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	700000	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	832000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Cuentas, Inc. (the “Company”) together with its subsidiaries, is mainly focused on financial technology (“FINTECH”) services, delivering mobile financial services, prepaid debit and digital content services to unbanked, underbanked and underserved communities. During 2023-Q1, the Company initiated its first investment into the Real Estate market and, made its second, more significant investment in Real Estate in the second quarter of 2023. The Company derived its revenue from wholesale telecommunication services, GPR “Debit” Card fees and the sales of prepaid products and services including third party digital content, gift cards, remittances, mobile phone topups and other digital services. Additionally, the Company has an agreement with Interactive Communications International, Inc. (“InComm”) a leading processor of general purpose reloadable (“GPR”) debit cards, to market and distribute a line of prepaid digital content and gift cards targeted towards the Latin American market. Cuentas is able to purchase InComm’s prepaid digital content and gift cards at a discount and resell these same products in real time through its mobile app and through the Cuentas SDI network of over 31,000 bodegas. Cuentas is able to offer these digital products to the public through its mobile app and the Cuentas SDI distribution network, many at discounted prices, while making a small profit margin which varies from product to product.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Company was incorporated under the laws of the State of Florida on September 21, 2005. Its subsidiary, Meimoun and Mammon, LLC (100% owned) (“M&M”), Tel3, a business segment of the Company, provides prepaid calling cards to consumers directly and operates in a complimentary space as Meimoun and Mammon, LLC. The Company invested $46, of which $20 were invested during 2023, for 50% of CUENTASMAX LLC which installs WiFi6 shared network (“WSN”) systems in locations in the New York metropolitan tristate area using access points and small cells to provide users with access to the WSN.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">NASDAQ</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 18, 2023, the Company received a deficiency letter from Nasdaq Regulation stating that based upon its Quarterly Report on Form 10-Q for the period ended June 30, 2023 which reported shareholders’ equity of $1,471, the Company was not in compliance with Nasdaq Marketplace Rule 5550(b)(1) which requires the Company to maintain shareholders’ equity of not less than $2,500 for continued listing on The Nasdaq Capital Market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On October 3 2023, the Company received a Staff Determination Letter from Nasdaq Regulation stating that due to the Company’s failure by October 2, 2023, to submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1), the $2,500 stockholders’ equity requirement, the Company would be subject to delisting unless it timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”). The Company has requested a hearing before the Panel which was held on December 7, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On December 18, 2023, the Company received written notice from the Panel notifying the Company that the panel has determined to delist the Company’s shares and warrants from Nasdaq and that trading of its common stock and warrants will be suspended as of the opening of business on December 20, 2023. Company securities began trading on the Pink Current Information tier of the over-the-counter market operated by OTC Markets Group effective with the open of business on December 20, 2023, under its trading symbol: CUEN.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">REVERSE SPLIT</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On March 24, 2023, the Company completed a reverse stock split of its common stock. As a result of the reverse stock split, the following changes have occurred (i) every thirteen shares of common stock have been combined into one share of common stock; (ii) the number of authorized shares of common stock has been proportionately reduced; (iii) the number of shares of common stock underlying each common stock option or common stock warrant have been proportionately decreased on a 1-for-13 basis, and (iv) the exercise price of each such outstanding stock option and common warrant has been proportionately increased on a 1-for-13 basis. Accordingly, all option numbers, share numbers, warrant numbers, share prices, warrant prices, exercise prices and losses per share have been adjusted within these consolidated financial statements, on a retroactive basis, to reflect this 1-for-13 reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">GOING CONCERN</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As of December 31, 2023, the Company had $205 in cash and cash equivalents, $2,929 in negative working capital, shareholder’s deficit of $70 and an accumulated deficit of $54,946. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Company’s ability to continue as a going concern is dependent upon raising capital from financing transactions and revenue from operations. Management anticipates their business will require substantial additional investments that have not yet been secured. Management is continuing in the process of fund raising in the private equity and capital markets as the Company will need to finance future activities. The Company, through M&M is negotiating to sell mobile services as a Mobile Virtual Network Operator (“MVNO”) through an operator on the largest 5G nationwide network and plans to offer low-cost mobile phone service with the ability to make international calls to specific Spanish speaking countries in Central and South America. In addition, as noted in note 14, on March 13, 2024, the Company approved the signing of a letter of intent to sell the “Brooksville Property” for gross proceeds of $7,200 (see note 14 for further information). These financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</p>
CY2023Q4	cuen	Cuentas Sdi Network Of Over Bodegas CuentasSDINetworkOfOverBodegas	31000	pure
CY2023	us-gaap	Payments To Acquire Projects PaymentsToAcquireProjects	46000	usd
CY2023Q3	cuen	Nasdaq Shareholders Equity Marketplace Rule NasdaqShareholdersEquityMarketplaceRule	1471000	usd
CY2023Q4	cuen	Nasdaq Shareholders Equity Marketplace Rule NasdaqShareholdersEquityMarketplaceRule	2500000	usd
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	As a result of the reverse stock split, the following changes have occurred (i) every thirteen shares of common stock have been combined into one share of common stock; (ii) the number of authorized shares of common stock has been proportionately reduced; (iii) the number of shares of common stock underlying each common stock option or common stock warrant have been proportionately decreased on a 1-for-13 basis, and (iv) the exercise price of each such outstanding stock option and common warrant has been proportionately increased on a 1-for-13 basis. Accordingly, all option numbers, share numbers, warrant numbers, share prices, warrant prices, exercise prices and losses per share have been adjusted within these consolidated financial statements, on a retroactive basis, to reflect this 1-for-13 reverse stock split.
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	205000	usd
CY2023	cuen	Working Capital WorkingCapital	2929000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-70000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54946000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Use of Estimates</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“‘US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to the consolidated financial statements, the most significant estimates and assumptions relate to allowances for impairment of intangible assets, fair value of derivative warrants and fair value of stock-based compensation.</p>
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Depreciation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation	0.33	pure
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3600000	usd
CY2023	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>J.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Revenue Recognition</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company follows paragraph 605-10-S99 of the FASB Accounting Standards Codification for revenue recognition. The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable and (iv) collectability is reasonably assured. The Company primarily generates revenues through the brokering of sales of minutes from one telecommunications carrier to another and to a lesser extent the sales of prepaid calling minutes to consumers through its Tel3 division. While the Company collects payment for such minutes in advance, revenue is recognized upon delivery to and consumption of minutes by the consumer. Bonus minutes granted by the company to its customers are forfeited after twelve consecutive months of non-use at which point the Company recognizes revenue from the forfeiture of prepaid minutes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (ASC 606), when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expect to receive in exchange for those goods or services. To determine whether arrangements are within the scope of ASC 606, the Company perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligation. The Company apply the five-step model to contracts when it is probable that the Company will collect the consideration the Company are entitled to in exchange for the goods or services the Company transfer to the customer. At contract inception, once the contract is determined to be within the scope of this guidance, the Company assessed the goods or services promised within each contract and identify, as a performance obligation, and assess whether each promised good or service is distinct. The Company then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>L.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Concentrations of credit risk</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in Dollars, are deposited with major banks in the United States. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	84999	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	128477	shares
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	2928000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	776000	usd
CY2023Q4	cuen	Common Stock Shares Outstanding Percentage CommonStockSharesOutstandingPercentage	0.1999	pure
CY2023Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	700000	usd
CY2023Q2	us-gaap	Area Of Land AreaOfLand	21.8	acre
CY2023	cuen	Interest Percentage InterestPercentage	0.63	pure
CY2023Q4	us-gaap	Collateralized Agreements CollateralizedAgreements	240000	usd
CY2023	cuen	Additional Fund AdditionalFund	127.5
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	92000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	8000	usd
CY2022Q2	us-gaap	Loans And Leases Receivable Net Reported Amount LoansAndLeasesReceivableNetReportedAmount	750000000	usd
CY2022Q2	us-gaap	Loans Assumed1 LoansAssumed1	100000000	usd
CY2023Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	850000	usd
CY2023Q2	us-gaap	Impairment Of Investments ImpairmentOfInvestments	537000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	9047000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9028000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	19000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	47000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9019000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	28000	usd
CY2019Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	9000000	usd
CY2019Q4	cuen	Shares Of Common Stock Percentage SharesOfCommonStockPercentage	0.25	pure
CY2022Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	3600000	usd
CY2021Q1	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	47000	usd
CY2021Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P60M
CY2023Q2	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	303000	usd
CY2023Q2	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	301000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	10000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	9000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	19000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1810000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2135000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	309000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	95000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	105000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	267000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2230000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	681000	usd
CY2023	cuen	Issued To Investors IssuedToInvestors	8049000	usd
CY2023	cuen	Issued To Placement Agents IssuedToPlacementAgents	420000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	832000	usd
CY2023	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	-6852000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	785000	usd
CY2023	us-gaap	Management And Service Fees Incentive Rate ManagementAndServiceFeesIncentiveRate	1	pure
CY2023	cuen	Bonus Payment BonusPayment	0.025	pure
CY2023	cuen	Equity Interest EquityInterest	0.10	pure
CY2023	us-gaap	Payment For Incentive Fee PaymentForIncentiveFee	100000000	usd
CY2023	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	285000	usd
CY2023	cuen	Annual Performance Percentage AnnualPerformancePercentage	1	pure
CY2023Q4	cuen	Ownership Percentage OwnershipPercentage	0.07	pure
CY2023	cuen	Shares To Be Issued Percentage SharesToBeIssuedPercentage	0.50	pure
CY2023	cuen	Equity Percentage EquityPercentage	0.07	pure
CY2023Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	109312	shares
CY2023Q4	us-gaap	Valuation Allowance For Impairment Of Recognized Servicing Assets Balance ValuationAllowanceForImpairmentOfRecognizedServicingAssetsBalance	2000	usd
CY2023Q4	us-gaap	Incentive Fee Payable IncentiveFeePayable	100000000	usd
CY2019Q4	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	9000000	usd
CY2023	cuen	License Paid LicensePaid	640000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	12307	shares
CY2022Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	420000	usd
CY2023	cuen	Receipt Of The Payment ReceiptOfThePayment	350000	usd
CY2023Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	172000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1300000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	198000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1472000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	198000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	121938	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	47.97
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	38461	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	36.4
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	31922	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	36.4
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	128477	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	56.44
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	34616	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	36.4
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	8862	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	158.73
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	84999	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	36.97
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	84999	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	36.97
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	36.4
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	36.4
CY2022Q2	cuen	Fair Value Options FairValueOptions	134000	usd
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	36.4
CY2022Q1	cuen	Stock Based Vested Options StockBasedVestedOptions	3847000	usd
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	213000	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	680	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2366	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	37000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1587000	usd
CY2022Q3	cuen	Common Stock Purchase Shares CommonStockPurchaseShares	324928	shares
CY2023	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	165000	usd
CY2023Q1	us-gaap	Market Risk Benefit Change In Fair Value Gain Loss MarketRiskBenefitChangeInFairValueGainLoss	112000	usd
CY2023Q1	us-gaap	Market Risk Benefit Change In Fair Value Gain Loss MarketRiskBenefitChangeInFairValueGainLoss	143000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	5000000	usd
CY2023Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	163344	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	128031	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.16
CY2023Q1	us-gaap	Sale Of Stock Percentage Of Ownership Before Transaction SaleOfStockPercentageOfOwnershipBeforeTransaction	0.0499	pure
CY2023Q1	cuen	Investor Percentage InvestorPercentage	0.0999	pure
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	0.0013
CY2023	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	17.36
CY2023	cuen	Cash Fee Equal Percentage CashFeeEqualPercentage	0.07	pure
CY2023	cuen	Nonaccountable Expense nonaccountableExpense	65000	usd
CY2023	cuen	Clearing Expenses ClearingExpenses	16000	usd
CY2023	cuen	Warrant Term WarrantTerm	P5Y
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	23.17
CY2023Q4	cuen	Offering Expenses OfferingExpenses	4319000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.67
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.16
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	616303	shares
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.3
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2033799000	usd
CY2023	us-gaap	Cash Flows Between Transferee And Transferor Servicing Fees CashFlowsBetweenTransfereeAndTransferorServicingFees	142366000	usd
CY2023Q4	cuen	Cash Fee Gross Proceeds CashFeeGrossProceeds	0.07	pure
CY2023	cuen	Management Fees ManagementFees	20338000	usd
CY2023	cuen	Management Fee Equal Percentage ManagementFeeEqualPercentage	0.01	pure
CY2023Q4	cuen	Non Accountable Expenses NonAccountableExpenses	65000000	usd
CY2023Q4	cuen	Closing Fee ClosingFee	15950000	usd
CY2019Q2	us-gaap	Other Receivables OtherReceivables	1053000	usd
CY2021Q3	us-gaap	Affiliate Costs AffiliateCosts	600000	usd
CY2023	cuen	Accrued Amount AccruedAmount	300000	usd
CY2022Q4	us-gaap	Product Liability Contingency Loss Exposure In Excess Of Accrual Best Estimate ProductLiabilityContingencyLossExposureInExcessOfAccrualBestEstimate	630000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Settlements Plan Assets DefinedBenefitPlanSettlementsPlanAssets	20000	usd
CY2023	us-gaap	Payments For Fees PaymentsForFees	15000	usd
CY2023	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	425000	usd
CY2023Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	145000	usd
CY2023Q1	us-gaap	Defined Benefit Plan Settlements Plan Assets DefinedBenefitPlanSettlementsPlanAssets	30000	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	9000	usd
CY2023Q3	cuen	Payment Of Outstanding Invoice PaymentOfOutstandingInvoice	229000	usd
CY2023	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	21000	usd
CY2023	us-gaap	Revenues Revenues	2346000	usd
CY2022	us-gaap	Revenues Revenues	2994000	usd
CY2023	us-gaap	Gross Profit GrossProfit	-387000	usd
CY2022	us-gaap	Gross Profit GrossProfit	486000	usd
CY2023	cuen	Long Lived Assetsloss By Product LongLivedAssetslossByProduct	13000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.50	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	2196000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	14479000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.265	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.265	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	582000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	3837000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-54000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1254000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1854000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1782000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1983000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1230577	shares
CY2023	cuen	Stock Issued During Period Value Stock Splits StockIssuedDuringPeriodValueStockSplits		usd
CY2023	cuen	Loan To Cuentas Sdillc That Was Not Repaid LoanToCuentasSDILLCThatWasNotRepaid		usd
CY2023Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	10305000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	8523000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10305000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8523000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8523000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1782000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10305000	usd
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2317213	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1230577	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1523849	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	603514	shares
CY2023Q3	us-gaap	Loans Payable LoansPayable	500000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.81
CY2023	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses		usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges		usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties		usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets		usd
CY2023	cuen	Investment In Nonconsolidated Entity In Nonconsolidated Entity Against Accounts Receivables InvestmentInNonconsolidatedEntityInNonconsolidatedEntityAgainstAccountsReceivables		usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent		usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2022	cuen	Issued To Investors IssuedToInvestors		usd
CY2022	cuen	Issued To Placement Agents IssuedToPlacementAgents		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment		usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2022Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	cuen	Long Lived Assetsloss By Product LongLivedAssetslossByProduct		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount		usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense		usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001424657
CY2023	dei	No Trading Symbol Flag NoTradingSymbolFlag	true

Files In Submission

Name	View Source	Status
0001213900-24-032958-index-headers.html	Edgar Link	pending
0001213900-24-032958-index.html	Edgar Link	pending
0001213900-24-032958.txt	Edgar Link	pending
0001213900-24-032958-xbrl.zip	Edgar Link	pending
cuen-20231231.xsd	Edgar Link	pending
cuen-20231231_cal.xml	Edgar Link	unprocessable
ea0202458-10k_cuentas.htm	Edgar Link	pending
ea020245801ex10-21_cuentas.htm	Edgar Link	pending
ea020245801ex10-25_cuentas.htm	Edgar Link	pending
ea020245801ex10-28_cuentas.htm	Edgar Link	pending
ea020245801ex14-1_cuentas.htm	Edgar Link	pending
ea020245801ex19-1_cuentas.htm	Edgar Link	pending
ea020245801ex21-1_cuentas.htm	Edgar Link	pending
ea020245801ex23-1_cuentas.htm	Edgar Link	pending
ea020245801ex31-1_cuentas.htm	Edgar Link	pending
ea020245801ex31-2_cuentas.htm	Edgar Link	pending
ea020245801ex32-1_cuentas.htm	Edgar Link	pending
ea020245801ex32-2_cuentas.htm	Edgar Link	pending
ea020245801ex4-9_cuentasinc.htm	Edgar Link	pending
ea020245801ex97-1_cuentas.htm	Edgar Link	pending
ex10-25_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
cuen-20231231_lab.xml	Edgar Link	unprocessable
cuen-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cuen-20231231_def.xml	Edgar Link	unprocessable
ea0202458-10k_cuentas_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CUEN
Cuentas Inc. Stock $cuen

2024 Q1 Form 10-K Financial Statement

#000121390024032958 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CUEN Cuentas Inc. Stock $cuen

2024 Q1 Form 10-K Financial Statement

#000121390024032958 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CUEN
Cuentas Inc. Stock $cuen